NeoGenomics announced pricing of $275 million in 0.75% convertible senior notes maturing July 1, 2032, with an additional $41.25 million option for underwriters. The notes carry an initial conversion price of $14.16 per share, representing a 35% premium to the June 16 closing price, providing the company capital for operations and strategic initiatives.